Last reviewed · How we verify

NCT05596864

Transabdominal Gastric Contrast Ultrasound

Status unknown Last updated 27 October 2022
What this trial tests

trial testing gastric contrast ultrasound in Transabdominal Gastric Contrast Ultrasound in 1,000 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
30 June 2024
30 December 2024

Quick facts

Lead sponsorThe First Hospital of Jilin University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 December 2022
Primary completion30 June 2024
Estimated completion30 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

The First Hospital of Jilin University

Who can join

Adults 18 to 80, any sex, with Transabdominal Gastric Contrast Ultrasound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the clinical data of patients diagnosed with gastric cancer who were ready for surgery were examined by contrast-enhanced ultrasonography and gastric-enhanced CT before surgery. Based on the results of postoperative pathological examinations, the diagnostic accuracy of gastric filling contrast-enhanced ultrasonography and gastric contrast-enhanced CT in different stages of gastric cancer was compared and analyzed. Provide better guidance for follow-up clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The First Hospital of Jilin University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05596864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing